Physician profile
Max Halpern
NPI 1437491073
$2,412.84
in general payments reported to CMS, 2019-2025
24 companies · $357 in 2025
The $357 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $394 · 2021: $498 · 2022: $195 · 2023: $283 · 2024: $229 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $422.58 | 2020-2025 | Vpriv |
| Cranial Technologies, INC | $343.14 | 2020-2025 | Doc Band |
| Glaxosmithkline, LLC. | $323.63 | 2019-2025 | Bexsero |
| Tris Pharma INC | $184.08 | 2019-2021 | |
| Kaleo, INC. | $175.95 | 2021-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $129.73 | 2019-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Janssen Pharmaceuticals, INC | $124.99 | 2020 | |
| Neos Therapeutics, Lp | $85.60 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Sanofi Pasteur INC. | $73.96 | 2021-2024 | |
| Genentech USA, INC. | $70.45 | 2019-2020 | |
| Sobi, INC | $64.78 | 2019-2021 | |
| Baxter Healthcare | $54.31 | 2022 | |
| Alexion Pharmaceuticals, INC. | $50.83 | 2025 | Koselugo |
| Seqirus USA INC | $48.09 | 2025 | Flucelvax |
| Avion Pharmaceuticals | $43.61 | 2023 | Methylphenidate Hydrochloride |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $39.09 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $38.59 | 2025 | Neffy |
| Corium, LLC | $25.91 | 2024 | Azstarys |
| Pfizer INC. | $25.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $22.72 | 2024 | Relexxii |
| Ironshore Pharmaceuticals INC. | $22.35 | 2019 | |
| Alk-Abello, INC | $16.67 | 2025 | Neffy |
| Arbor Pharmaceuticals, INC. | $13.51 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Halpern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.